

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
CONVEYING PARTY DATA													
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Martin ALLAN</td> <td>11/17/2010</td> </tr> <tr> <td>Sylvie CHAMOIN</td> <td>11/16/2010</td> </tr> <tr> <td>Qi-Ying HU</td> <td>11/18/2010</td> </tr> <tr> <td>Hidetomo IMASE</td> <td>11/17/2010</td> </tr> <tr> <td>Julien PAPILLON</td> <td>11/17/2010</td> </tr> </tbody> </table>		Name	Execution Date	Martin ALLAN	11/17/2010	Sylvie CHAMOIN	11/16/2010	Qi-Ying HU	11/18/2010	Hidetomo IMASE	11/17/2010	Julien PAPILLON	11/17/2010
Name	Execution Date												
Martin ALLAN	11/17/2010												
Sylvie CHAMOIN	11/16/2010												
Qi-Ying HU	11/18/2010												
Hidetomo IMASE	11/17/2010												
Julien PAPILLON	11/17/2010												
RECEIVING PARTY DATA													
Name:	NOVARTIS AG												
Street Address:	Lichtstrasse 35												
City:	Basel												
State/Country:	SWITZERLAND												
Postal Code:	4056												
PROPERTY NUMBERS Total: 1													
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13509646</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13509646								
Property Type	Number												
Application Number:	13509646												
CORRESPONDENCE DATA													
Fax Number:	(617)871-3392												
Phone:	617 871 3013												
Email:	pip_inbox.phchbs@novartis.com												
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>													
Correspondent Name:	Marilyn Murphy												
Address Line 1:	220 Massachusetts Avenue												
Address Line 2:	NIBR												
Address Line 4:	Cambridge, MASSACHUSETTS 02139												
ATTORNEY DOCKET NUMBER:	PAT053872 US-PCT												
NAME OF SUBMITTER:	Marilyn Murphy												

CH \$40.00 13509646

**Total Attachments: 12**

source=Assignment(signed)#page1.tif  
source=Assignment(signed)#page2.tif  
source=Assignment(signed)#page3.tif  
source=Assignment(signed)#page4.tif  
source=Assignment(signed)#page5.tif  
source=Assignment(signed)#page6.tif  
source=Assignment(signed)#page7.tif  
source=Assignment(signed)#page8.tif  
source=Assignment(signed)#page9.tif  
source=Assignment(signed)#page10.tif  
source=Assignment(signed)#page11.tif  
source=Assignment(signed)#page12.tif

(joint)

Patent Case PAT053872

### ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

Martin ALLAN	citizen of Canada	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Sylvie CHAMOIN	citizen of France	Novartis Pharma AG Postfach 4002 Basel CH
Qi-Ying HU	citizen of China	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Hidetomo IMASE	citizen of Japan	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 USA
Julien PAPILLON	citizen of France	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, (hereinafter referred to as the "ASSIGNEE") and its successors, assigns and legal representatives, all of my right, title and interest for all countries of the world in and to (1) all of my inventions and discoveries described in the patent application(s) titled

#### ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS

and filed in the United States Patent and Trademark Office on \_\_\_\_\_, 20\_\_ and accorded Application Number \_\_\_\_\_\* and/or filed in the RO/ \_\_\_\_\_ on \_\_\_\_\_, 20\_\_ and accorded International Patent Application Number PCT/ \_\_\_\_\_\*, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on November 17, 2009 and accorded Application Number 61/261,948, (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for

said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

\*We hereby authorize ASSIGNEE and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of ASSIGNEE or their successors, assigns or legal representatives execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates and applications within the scope of (8) and (9) in ASSIGNEE or their successors, assigns or legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE or their successors, assigns or legal representatives execute all additional patent applications within the scope of (3), (4) and (6) and all applications within the scope of (8) or (9) and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE or their successors, assigns or legal representatives.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 17 day of November, 2010


Martin Allan  L.S.

**ACKNOWLEDGEMENT**

State of Massachusetts )  
 ) s.s.:  
County of Middlesex )

On this 17th day of November, 2010 personally appeared before me Martin Allan to me known and known by me to be the same person described in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her) own free will for the purpose set forth.

(Seal)

  
Notary Public  
Jessica M. Yee  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires  
May 17, 2011



Executed this 17 day of Nov, 2010.

[Signature]  
Hidetomo Imase L.S.

**ACKNOWLEDGEMENT**

State of Massachusetts )  
 ) s.s.:  
County of Middlesex )

On this 17<sup>th</sup> day of November, 2010 personally appeared before me Hidetomo Imase to me known and known by me to be the same person described in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her) own free will for the purpose set forth.

(Seal)

[Signature]  
Notary Public

James M. York  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires  
May 19, 2011

Executed this 17<sup>th</sup> day of November, 2010.

[Signature]  
Julien Papillon L.S.

**ACKNOWLEDGEMENT**

State of Massachusetts )  
 ) s.s.:  
County of Middlesex )

On this 17<sup>th</sup> day of November, 2010, personally appeared before me Julien Papillon to me known and known by me to be the same person described in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her) own free will for the purpose set forth.

(Seal)

[Signature]  
Notary Public

James M. York  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires  
May 19, 2011

ACCEPTANCE OF ASSIGNMENT

With reference to the Assignment to NOVARTIS AG of an invention entitled "ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS" signed by Martin Allan, Sylvie Chamoin, Qi-Ying Hu, Hidetomo Imase and Julien Papillon; this will certify that NOVARTIS AG accepts such Assignment.

NOVARTIS AG

By:

E. Rutschmann

R. Halbeisen

Name :

Ella Rutschmann

Reto Halbeisen

Function :

Authorized Signatory

Authorized Signatory

Date:

22.11.2010

**ATTESTATION**

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin certify herewith that the signatures attached heretofore are the genuine signatures of **Ms. Ella Rutschmann**, citizen of Lotzwil, Switzerland, residing in Basel, Switzerland; and of **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Laufen, Switzerland; both acting for **Novartis AG**, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signatures was established by comparison.

BASEL, Switzerland, this 9<sup>th</sup> (ninth) day of December 2010 (two thousand and ten)

*M. Staehelin, Notar*

Dr. M. Staehelin  
Notar

Leg. Prot. Nr.: 2652/2010



07/08

(joint)

Patent Case PAT053872

### ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

Martin ALLAN	citizen of Canada	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Sylvie CHAMOIN	citizen of France	Novartis Pharma AG Postfach 4002 Basel CH
Qi-Ying HU	citizen of China	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US
Hidetomo IMASE	citizen of Japan	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 USA
Julian PAPILLON	citizen of France	Novartis Institutes for BioMedical Research, Inc. 100 Technology Square Cambridge, MA 02139 US

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, (hereinafter referred to as the "ASSIGNEE") and its successors, assigns and legal representatives, all of my right, title and interest for all countries of the world in and to (1) all of my inventions and discoveries described in the patent application(s) titled

#### ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS

and filed in the United States Patent and Trademark Office on \_\_\_\_\_, 20\_\_ and accorded Application Number \_\_\_\_\_\* and/or filed in the RO/ \_\_\_\_\_ on \_\_\_\_\_, 20\_\_ and accorded International Patent Application Number PCT/ \_\_\_\_\_\*, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on November 17, 2009 and accorded Application Number 61/261,948, (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for







ACCEPTANCE OF ASSIGNMENT

With reference to the Assignment to NOVARTIS AG of an invention entitled "ARYL-PYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS" signed by Martin Allan, Sylvie Chamoin, Qi-Ying Hu, Hidetomo Imase and Julien Papillon; this will certify that NOVARTIS AG accepts such Assignment.

NOVARTIS AG

By: E. Rutschmann

Name: Ella Rutschmann

Function: Authorized Signatory

Date: 22.11.2010

R. Halbeisen

Reto Halbeisen

Authorized Signatory

**ATTESTATION**

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine signature of **Ms. Sylvie Chamoin**, French citizen, residing in Saint Louis, France.

I further certify that the signatures attached heretofore are the genuine signatures of **Ms. Ella Rutschmann**, citizen of Lotzwil, Switzerland, residing in Basel, Switzerland, and of **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Laufen, Switzerland, both acting for **Novartis AG**, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 9<sup>th</sup> (ninth) day of December 2010 (two thousand and ten)

*M. Staehelin, Notar*

Dr. M. Staehelin  
Notar

Leg. Prot. Nr. 2651/2010